Detailed Mechanism Funding and Narrative

Years of mechanism: 2012 2013 2014 2015 2016 2017 2018

Details for Mechanism ID: 13929
Country/Region: Ethiopia
Year: 2016
Main Partner: Dire Dawa City Administration Health Bureau
Main Partner Program: NA
Organizational Type: Host Country Government Agency
Funding Agency: HHS/CDC
Total Funding: $1,280,554 Additional Pipeline Funding: N/A

NOTE: PEPFAR no longer creates activity narratives for each mechanism. In their place, PEPFAR has begun releasing mechanism specific targets that reveal the achievements and programs that are expected of the funding. If available for this mechanism, these targets are presented below.

Mechanism Allocation by Budget Code for Selected Year
Care: Adult Care and Support (HBHC) $105,496
Care: TB/HIV (HVTB) $115,087
Care: Pediatric Care and Support (PDCS) $21,431
Laboratory Infrastructure (HLAB) $43,344
Strategic Information (HVSI) $24,796
Health Systems Strengthening (OHSS) $38,528
Biomedical Prevention: Blood Safety (HMBL) $12,654
Testing: HIV Testing and Counseling (HVCT) $42,381
Sexual Prevention: Other Sexual Prevention (HVOP) $17,600
Biomedical Prevention: Prevention of Mother to Child Transmission (MTCT) $52,475
Treatment: Adult Treatment (HTXS) $748,469
Treatment: Pediatric Treatment (PDTX) $58,293
Mechanism Target Information

Since COP2014, PEPFAR no longer produces narratives for every mechanism it funds. However, PEPFAR has now included performance targets or indicator information for each mechanism based on the Monitoring, Evaluation, and Reporting (MER) system. The MER guidance is available on PEPFAR's website https://www.pepfar.gov/reports/guidance/. Note that COP years 2014-2015 were under a previous version of the MER system and the indicators and definitions may have changed as of the new 2.0 guidance.

MER Indicator MER description Target Fiscal Year Target
GEND_GBV By PEP service provision (related to sexual violence services provided) 2017 59
GEND_GBV By type of service: Physical and/or Emotional Violence (Other Post-GBV Care) 2017 42
GEND_GBV By type of service: Sexual Violence (Post-Rape Care) 2017 63
GEND_GBV Number of people receiving post-GBV care 2017 105
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female 2017 2,925
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male 2017 3,044
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female 2017 45,096
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male 2017 28,112
HTS_TST Number of individuals who received T&C services for HIV and received their test results during the past 12 months 2017 79,177
HTS_TST Service Delivery Point (Facility): Inpatient 2017 2,546
HTS_TST Service Delivery Point (Facility): Other PITC 2017 4,797
HTS_TST Service Delivery Point (Facility): Outpatient 2017 36,259
HTS_TST Service Delivery Point (Facility): PMTCT 2017 19,146
HTS_TST Service Delivery Point (Facility): TB Clinics 2017 1,419
HTS_TST Service Delivery Point (Facility): VCT 2017 15,010
HTS_TST Sum of Aggregated Age/Sex <15 2017 5,969
HTS_TST Sum of Aggregated Age/Sex 15+ 2017 73,208
HTS_TST Sum of Aggregated Age/Sex disaggregates 2017 79,177
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive <15 Female 2017 43
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive <15 Male 2017 44
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive 15+ Female 2017 610
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive 15+ Male 2017 276
KP_PREV By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) 2017 450
KP_PREV Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required 2017 450
KP_PREV Total estimated number of key population in the catchment area 2017 1,798
KP_PREV_den By key population type: Female sex workers (FSW) (Denominator: Total estimated number of key population in the catchment area) 2017 1,798
LAB_PT CD4: Number of laboratories that achieve acceptable successful passing criteria in this PT program 2017 4
LAB_PT CD4: Number of laboratories that participate in this PT program 2017 4
LAB_PT CD4: Number of laboratories that perform this testing 2017 5
LAB_PT HIV serologic/diagnostic testing: Number of laboratories that achieve acceptable successful passing criteria in this PT program 2017 12
LAB_PT HIV serologic/diagnostic testing: Number of laboratories that participate in this PT program 2017 12
LAB_PT HIV serologic/diagnostic testing: Number of laboratories that perform this testing 2017 12
LAB_PT TB diagnostics (AFB microscopy): Number of laboratories that achieve acceptable successful passing criteria in this PT program 2017 4
LAB_PT TB diagnostics (AFB microscopy): Number of laboratories that participate in this PT program 2017 4
LAB_PT TB diagnostics (AFB microscopy): Number of laboratories that perform this testing 2017 12
LAB_PT TB diagnostics (Xpert MTB/RIF): Number of laboratories that achieve acceptable successful passing criteria in this PT program 2017 1
LAB_PT TB diagnostics (Xpert MTB/RIF): Number of laboratories that participate in this PT program 2017 1
LAB_PT TB diagnostics (Xpert MTB/RIF): Number of laboratories that perform this testing 2017 1
PMTCT_ART Already on ART at beginning of current pregnancy 2017 17
PMTCT_ART Already on ART at beginning of current pregnancy 2017 142
PMTCT_ART New on ART 2017 1
PMTCT_ART New on ART 2017 68
PMTCT_ART Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2017 980
PMTCT_ART Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2017 19,297
PMTCT_EID By infants who received a virologic test within 2 months of birth 2017 22
PMTCT_EID By infants who received a virologic test within 2 months of birth 2017 164
PMTCT_EID By infants who received their first virologic HIV test between 2 and 12 months of age 2017 5
PMTCT_EID By infants who received their first virologic HIV test between 2 and 12 months of age 2017 41
PMTCT_EID Number of infants with a positive virological test result within 2 months of birth 2017 1
PMTCT_EID Number of infants with a positive virological test result within 2 months of birth 2017 4
PMTCT_EID Sum of Infant Age disaggregates 2017 27
PMTCT_EID Sum of Infant Age disaggregates 2017 205
PMTCT_STAT By: Known positives at entry 2017 19
PMTCT_STAT By: Known positives at entry 2017 151
PMTCT_STAT By: Number of new positives identified 2017 2
PMTCT_STAT By: Number of new positives identified 2017 68
PMTCT_STAT Number of new ANC and L&D clients 2017 1,044
PMTCT_STAT Number of new ANC and L&D clients 2017 20,313
PMTCT_STAT Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2017 980
PMTCT_STAT Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2017 19,297
PMTCT_STAT Sum of Positives Status disaggregates 2017 21
PMTCT_STAT Sum of Positives Status disaggregates 2017 219
PP_PREV Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period 2017 2,545
PP_PREV Total number of people in the target population 2017 3,052
TB_ART Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2017 12
TB_ART Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2017 72
TB_ART Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2017 19
TB_ART Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2017 96
TB_ART The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period 2017 199
TB_ART The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period 2017 199
TB_SCREENDX [Sub-Disagg of Screen Result] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB 2017 483
TB_SCREENDX [Sub-Disagg of Specimen Sent] Diagnostic Test: other (not Xpert) 2017 143
TB_SCREENDX [Sub-Disagg of Specimen Sent] Diagnostic Test: Smear only 2017 147
TB_SCREENDX [Sub-Disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay 2017 193
TB_SCREENDX Screen Result: Screened Positive for TB 2017 691
TB_SCREENDX Screened for TB by Age/Sex: 15+ Female 2017 4,139
TB_SCREENDX Screened for TB by Age/Sex: 15+ Male 2017 2,219
TB_SCREENDX Screened for TB by Age/Sex:<15 Female 2017 214
TB_SCREENDX Screened for TB by Age/Sex:<15 Male 2017 336
TB_SCREENDX The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period 2017 6,908
TB_STAT Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2017 91
TB_STAT Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2017 533
TB_STAT Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2017 122
TB_STAT Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2017 674
TB_STAT Number of registered new and relapsed TB cases with documented HIV status, during the reporting period 2017 1,420
TB_STAT Total number of registered new and relapsed TB cases, during the reporting period 2017 1,449
TX_CURR Aggregated Age/Sex: <15 Female 2017 237
TX_CURR Aggregated Age/Sex: <15 Male 2017 374
TX_CURR Aggregated Age/Sex: 15+ Female 2017 4,613
TX_CURR Aggregated Age/Sex: 15+ Male 2017 2,470
TX_CURR Number of adults and children receiving antiretroviral therapy (ART) 2017 7,694
TX_CURR Sum of Aggregated Age/Sex <15 2017 611
TX_CURR Sum of Aggregated Age/Sex 15+ 2017 7,083
TX_CURR Sum of Aggregated Age/Sex disaggregates 2017 7,694
TX_NEW Aggregated Grouping by Age/Sex: <15 Female 2017 49
TX_NEW Aggregated Grouping by Age/Sex: <15 Male 2017 59
TX_NEW Aggregated Grouping by Age/Sex: 15+ Female 2017 632
TX_NEW Aggregated Grouping by Age/Sex: 15+ Male 2017 328
TX_NEW Number of adults and children newly enrolled on antiretroviral therapy (ART) 2017 1,068
TX_NEW Sum of Aggregated Age/Sex disaggregates 2017 1,068
TX_PVLS Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months 2017 4,987
TX_PVLS Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months 2017 3,989
TX_PVLS Numerator Aggregated Age/Sex: <15 Female 2017 126
TX_PVLS Numerator Aggregated Age/Sex: <15 Male 2017 196
TX_PVLS Numerator Aggregated Age/Sex: 15+ Female 2017 2,390
TX_PVLS Numerator Aggregated Age/Sex: 15+ Male 2017 1,277
TX_PVLS Numerator: Indication: Routine 2017 3,191
TX_PVLS Numerator: Indication: Targeted 2017 798
TX_PVLS_den Denominator Aggregated Age/Sex: <15 Female 2017 157
TX_PVLS_den Denominator Aggregated Age/Sex: <15 Male 2017 243
TX_PVLS_den Denominator Aggregated Age/Sex: 15+ Female 2017 2,989
TX_PVLS_den Denominator Aggregated Age/Sex: 15+ Male 2017 1,598
TX_PVLS_den Denominator: Indication: Routine 2017 3,991
TX_PVLS_den Denominator: Indication: Targeted 2017 996
TX_RET Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 29
TX_RET Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 35
TX_RET Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 338
TX_RET Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 186
TX_RET Number of adults and children who are still alive and on treatment at 12 months after initiating ART 2017 588
TX_RET Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up 2017 642
TX_RET_den Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 32
TX_RET_den Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 38
TX_RET_den Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 369
TX_RET_den Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 203
Cross Cutting Budget Categories and Known Amounts Total: $114,754
Food and Nutrition: Policy, Tools, and Service Delivery $13,714
Key Populations: Sex Workers $7,040
Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention
Training of health workers and community outreach workers
Collection and use of strategic information on SWs and clients
Monitoring and evaluation of SW programs
Procurement of condoms, lubricants, and other commodities essential to core HIV services for SWs
Gender: Gender Based Violence (GBV) $14,000
GBV Prevention
Collection and Use of Gender-related Strategic Information
Implementation
Capacity building
Monitoring and Evaluation
Post GBV Care
Collection and Use of Gender-related Strategic Information
Implementation
Capacity building
Monitoring and Evaluation
Motor Vehicles: Purchased $80,000